Nutraceuticals / Healthcare - Listed on 04 February 2026
Accretion Nutraveda (Nutraceuticals / Healthcare) closed its IPO window in 2026 and listed on NSE and BSE on 04 February 2026 at an upper band issue price of Rs 129, opening at Rs 191 for a listing gain of +48.1% and closing day one at Rs 191.2 (+48.2% on closing basis). The IPO was subscribed 1.91x overall - QIB 1.01x, HNI/NII 2.42x, Retail 2.19x. The total issue size was Rs 24.77 Cr (Fresh Issue Rs 24.77 Cr, OFS Rs 0 Cr). IPO GMP data, subscription trends across Day 1 - Day 3 and Nifty performance around the listing window are detailed below.
Nutraceuticals / Healthcare
Accretion Nutraveda operates in the Nutraceuticals / Healthcare space. The company’s listed profile is shaped by its operating niche, customer demand and ability to convert that demand into steady cash flows. Investors should read its exchange filings alongside the headline listing numbers for a fuller view of the business.
Issue structure, listing outcome and context
The Accretion Nutraveda issue was offered at an upper price of Rs 129 and raised approximately Rs 24.77 crore. The final outcome reflected a mix of subscription demand, valuation, market conditions and the company’s own operating story. Fresh issue and offer-for-sale details, where available, are shown in the issue metrics below.
Number of times each investor category subscribed by close of Day 3.
How overall subscription built up across the three-day issue window.
Grey market premium (GMP) tracked day-by-day across the IPO window. Absolute GMP is the premium in rupees over the upper issue price; GMP % is that premium as a percent of the issue price.
| Day | GMP (Rs) | GMP % |
|---|---|---|
| Day 1 | - | - |
| Day 2 | - | - |
| Day 3 | - | - |
| Day 4 | - | - |
| Day 5 | - | - |
How the broader market moved around the Accretion Nutraveda IPO window. Helpful for isolating how much of the listing gain came from company fundamentals vs. market tailwind.
Accretion Nutraveda IPO listed at +48.1% versus the upper issue price of Rs 129 on 04 February 2026.
Accretion Nutraveda IPO was subscribed 1.91x overall. QIB portion was subscribed 1.01x, HNI / NII 2.42x and Retail 2.19x.
Day-by-day IPO GMP data for Accretion Nutraveda is listed in the table above.